21 CFR Part 11 sets the bar for every pharmaceutical, biotech, and medical device organization: electronic records and signatures are only trustworthy if they're tied to a verified, unique individual who cannot reassign or share that identity. Authority checks must confirm only authorized individuals can access systems or modify records. Access privileges must follow least privilege, enforced through role-based controls. None of this is optional guidance — it's the legal condition under which a drug approval, a clinical trial result, or a batch record holds up under FDA inspection.
The stakes of getting this wrong aren't abstract. FDA inspections frequently cite exactly two failure patterns: inadequate audit trails, and access control weaknesses like password sharing. Either one can delay a product release or invalidate months of research.
Life sciences organizations are also accumulating a newer, less-governed identity surface: the APIs and service accounts that automate laboratory workflows, manufacturing execution, and reporting. These often run with elevated privileges and little of the governance applied to human users — yet a compromised or misconfigured service account can compromise the same data integrity Part 11 exists to protect.
Whiteswan governs human access to GxP systems with the unique-identity, least-privilege, audit-trail model Part 11 demands — no shared logins, every action traceable to one person, every credential scoped to what that role actually requires. The same engine extends to the service accounts and automated workflows research, manufacturing, and quality teams increasingly rely on, bringing non-human identity under the same governance instead of leaving it as the unmonitored exception inspectors are now trained to look for. As life sciences organizations begin using AI in regulated processes, the same chokepoint governs those AI agents' access — with the audit trail to show, on inspection, exactly who authorized what.
This page describes 21 CFR Part 11 and adjacent GxP requirements and how Whiteswan's general platform capabilities map to them. It does not represent a specific life sciences customer deployment.
See how one engine governs every identity in your estate.
Contact →See how Whiteswan decides, in-line, at the moment of action.
See how it works →